相似文献
1
Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy.
Br J Haematol. 2020 Jul;190(1):45-51. doi: 10.1111/bjh.16541. Epub 2020 Mar 5.
2
Incorporating radiation with anti-CD19 chimeric antigen receptor T-cell therapy for relapsed/refractory non-Hodgkin lymphoma: A multicenter consensus approach.
Am J Hematol. 2024 Jan;99(1):124-134. doi: 10.1002/ajh.27155. Epub 2023 Nov 11.
3
Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma.
Transplant Cell Ther. 2022 Jun;28(6):342.e1-342.e5. doi: 10.1016/j.jtct.2022.02.021. Epub 2022 Mar 4.
4
Salvage radiotherapy for relapsed/refractory non-Hodgkin lymphoma following CD19 chimeric antigen receptor T-cell (CART) therapy.
Clin Transl Radiat Oncol. 2023 Jan 20;39:100587. doi: 10.1016/j.ctro.2023.100587. eCollection 2023 Mar.
5
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Transplant Cell Ther. 2023 Sep;29(9):574.e1-574.e10. doi: 10.1016/j.jtct.2023.06.019. Epub 2023 Jun 30.
6
Don't Put the CART Before the Horse: The Role of Radiation Therapy in Peri-CAR T-cell Therapy for Aggressive B-cell Non-Hodgkin Lymphoma.
Int J Radiat Oncol Biol Phys. 2023 Aug 1;116(5):999-1007. doi: 10.1016/j.ijrobp.2022.12.017. Epub 2022 Dec 21.
7
ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Diffuse Large B-cell Lymphoma after Failure of Chimeric Antigen Receptor T Cell Therapy (CAR-T) Therapy.
Transplant Cell Ther. 2022 Sep;28(9):523-529. doi: 10.1016/j.jtct.2022.05.043. Epub 2022 Jun 6.
8
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Am J Hematol. 2021 Jun 1;96(6):671-679. doi: 10.1002/ajh.26160. Epub 2021 Mar 29.
9
[Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2019.04.003.
10
The Current and Future Role of Radiation Therapy in the Era of CAR T-cell Salvage.
Br J Radiol. 2021 Nov 1;94(1127):20210098. doi: 10.1259/bjr.20210098. Epub 2021 Aug 10.
引用本文的文献
1
CAR T-Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real-World Experiences From a Single Center on the Use of Radiotherapy.
Hematol Oncol. 2025 Sep;43(5):e70124. doi: 10.1002/hon.70124.
2
The Role of Radiotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post-CAR-T Therapy: A Systematic Literature Review.
Technol Cancer Res Treat. 2025 Jan-Dec;24:15330338251351065. doi: 10.1177/15330338251351065. Epub 2025 Jun 18.
3
[Radiotherapy of non-Hodgkin lymphoma-discussion of modern treatment concepts and innovations].
Radiologie (Heidelb). 2025 Jun 11. doi: 10.1007/s00117-025-01477-3.
4
Role of Radiation in Combination With CD30-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Hodgkin Lymphoma.
Adv Radiat Oncol. 2023 Dec 23;9(4):101428. doi: 10.1016/j.adro.2023.101428. eCollection 2024 Apr.
5
Treatment strategies for relapse after CAR T-cell therapy in B cell lymphoma.
Front Pediatr. 2024 Jan 12;11:1305657. doi: 10.3389/fped.2023.1305657. eCollection 2023.
6
Hypofractionated radiotherapy for refractory or relapsed aggressive B-cell lymphoma in the rituximab era.
BMC Cancer. 2024 Jan 13;24(1):72. doi: 10.1186/s12885-024-11837-2.
7
Management of aggressive lymphoma after CAR T-cell therapy failure.
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):364-369. doi: 10.1182/hematology.2023000437.
8
The CAR macrophage cells, a novel generation of chimeric antigen-based approach against solid tumors.
Biomark Res. 2023 Nov 28;11(1):103. doi: 10.1186/s40364-023-00537-x.
9
Application of interim PET-CT in first-line treatment decision-making for lymphoma.
J Zhejiang Univ Sci B. 2023 Oct 15;24(10):905-921. doi: 10.1631/jzus.B2200644.
10
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.
Exp Hematol Oncol. 2023 Aug 14;12(1):72. doi: 10.1186/s40164-023-00432-z.
本文引用的文献
1
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Blood. 2019 Aug 15;134(7):626-635. doi: 10.1182/blood.2018883421. Epub 2019 Jul 1.
2
Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma.
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1012-1021. doi: 10.1016/j.ijrobp.2019.05.065. Epub 2019 Jun 5.
3
BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.
Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.
4
Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.
5
Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation.
Front Oncol. 2018 Dec 13;8:612. doi: 10.3389/fonc.2018.00612. eCollection 2018.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape.
Mol Ther. 2018 Nov 7;26(11):2542-2552. doi: 10.1016/j.ymthe.2018.09.008. Epub 2018 Sep 13.
8
The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Best Pract Res Clin Haematol. 2018 Sep;31(3):293-298. doi: 10.1016/j.beha.2018.07.011. Epub 2018 Aug 1.
9
The influence of radiation in the context of developing combination immunotherapies in cancer.
Ther Adv Vaccines Immunother. 2017 Dec;5(6):115-122. doi: 10.1177/2051013617750561. Epub 2018 Jan 24.
10
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Int J Radiat Oncol Biol Phys. 2018 Mar 1;100(3):652-669. doi: 10.1016/j.ijrobp.2017.12.005.
Zotero 插件